Literature DB >> 11043537

Gene expression of PSD95 in prefrontal cortex and hippocampus in schizophrenia.

T Ohnuma1, H Kato, H Arai, R L Faull, P J McKenna, P C Emson.   

Abstract

A number of studies have suggested that disturbance in glutamatergic transmission in the cerebral cortex may underlie, or contribute to the pathophysiology of schizophrenia. In this study we examined expression of the postsynaptic density protein 95 (PSD95) mRNA in the prefrontal cortex and hippocampus in postmortem material from neuroleptic-treated schizophrenics and normal controls. PSD95 is known to bind to NMDA receptor subunits and is known to be involved in synaptic plasticity. In situ hybridization analysis showed that the expression of PSD95 was significantly decreased in Brodmann area 9 of the prefrontal cortex but not in the hippocampus. These results further implicate the prefrontal cortex in the pathophysiology of schizophrenia and suggest dysfunction of NMDA receptors in the schizophrenic cortex.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11043537     DOI: 10.1097/00001756-200009280-00019

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  33 in total

1.  Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder.

Authors:  Robert E McCullumsmith; Lars V Kristiansen; Monica Beneyto; Elizabeth Scarr; Brian Dean; James H Meador-Woodruff
Journal:  Brain Res       Date:  2006-11-17       Impact factor: 3.252

2.  Genetic variability in scaffolding proteins and risk for schizophrenia and autism-spectrum disorders: a systematic review.

Authors:  Jordi Soler; Lourdes Fañanás; Mara Parellada; Marie-Odile Krebs; Guy A Rouleau; Mar Fatjó-Vilas
Journal:  J Psychiatry Neurosci       Date:  2018-05-28       Impact factor: 6.186

Review 3.  Scaffolding proteins of the post-synaptic density contribute to synaptic plasticity by regulating receptor localization and distribution: relevance for neuropsychiatric diseases.

Authors:  Felice Iasevoli; Carmine Tomasetti; Andrea de Bartolomeis
Journal:  Neurochem Res       Date:  2012-09-19       Impact factor: 3.996

4.  Synaptic proteins in the hippocampus indicative of increased neuronal activity in CA3 in schizophrenia.

Authors:  Wei Li; Subroto Ghose; Kelly Gleason; Anita Begovic; Jessica Perez; John Bartko; Scott Russo; Anthony D Wagner; Lynn Selemon; Carol A Tamminga
Journal:  Am J Psychiatry       Date:  2015-01-13       Impact factor: 18.112

5.  Genetic variability in scaffolding proteins and risk for schizophrenia and autism-spectrum disorders: a systematic review.

Authors:  Jordi Soler; Lourdes Fañanás; Mara Parellada; Marie-Odile Krebs; Guy A Rouleau; Mar Fatjó-Vilas
Journal:  J Psychiatry Neurosci       Date:  2018-07       Impact factor: 6.186

Review 6.  Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications.

Authors:  Joseph T Coyle; Alo Basu; Michael Benneyworth; Darrick Balu; Glenn Konopaske
Journal:  Handb Exp Pharmacol       Date:  2012

Review 7.  PSD95: A synaptic protein implicated in schizophrenia or autism?

Authors:  Austin A Coley; Wen-Jun Gao
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-11-21       Impact factor: 5.067

Review 8.  Postmortem brain: an underutilized substrate for studying severe mental illness.

Authors:  Robert E McCullumsmith; John H Hammond; Dan Shan; James H Meador-Woodruff
Journal:  Neuropsychopharmacology       Date:  2013-10-04       Impact factor: 7.853

9.  Genetic and functional analysis of the DLG4 gene encoding the post-synaptic density protein 95 in schizophrenia.

Authors:  Min-Chih Cheng; Chao-Lin Lu; Sy-Ueng Luu; Ho-Min Tsai; Shih-Hsin Hsu; Tzu-Ting Chen; Chia-Hsiang Chen
Journal:  PLoS One       Date:  2010-12-02       Impact factor: 3.240

10.  Schizophrenia is associated with an increase in cortical microRNA biogenesis.

Authors:  N J Beveridge; E Gardiner; A P Carroll; P A Tooney; M J Cairns
Journal:  Mol Psychiatry       Date:  2009-09-01       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.